Sobi & Selecta Report Results of SEL-212 in P-II COMPARE Study for Chronic Refractory Gout Published: Oct 1, 2020 | Tags: Chronic Refractory Gout, COMPARE Study, Important Clinical Improvement, P-II, patients, reports, results, SEL-212, Selecta Biosciences, Sobi 2. Moderna’s mRNA-1273 COVID-19 Vaccine Demonstrate Immune Responses in Older Adults Published: Oct 1, 2020 | Tags: COVID-19, […]Read More
Shots: The P-II COMPARE study assessing SEL-212 (once monthly) vs pegloticase (twice monthly) in 170 patients with chronic refractory gout SEL-212 showed a numerically higher response rate on 1EP during 3 & 6 mos., but didn’t meet 1EP of superiority, higher response rate during 3 & 6mos., an overall reduction in mean SUA levels; patients […]Read More
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More
Shots: Shots: Florio GmbH has launched Florio, a digital medical device designed to improve the quality of life for people with hemophilia Florio consist of smartphone app combined with a wearable device and a web-based dashboard for physicians and allow patients to track, monitor and share data related to health in real-time with their health […]Read More
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More
1. RedHill Terminates its 2014 Deal with Salix Pharmaceuticals for RHB-106 Published: Jan 03, 2019 | Tags: 2014, Deal, RedHill, RHB-106, Salix Pharmaceuticals, Terminates 2. Innate’s Lumoxiti (moxetumomab pasudotox-tdfk) Receives EMA’s MAA to Treat Patients with Relapsed or Refractory Hairy Cell Leukemia Published: Jan 03, 2019 | Tags: EMA, Hairy Cell Leukemia, Innate, Lumoxit, MAA, […]Read More
Shots: Pharming to pay €7.5M in two tranches to Sobi and will reacquire exclusive rights to commercialize Ruconest in all remaining territories, which includes all remaining 36 EU markets and will be effective from Jan 1, 2020 Pharming to cooperate with Sobi for the replacement of all contracts for distribution and other services as quickly […]Read More
1. Pfizer’s Amsparity (biosimilar, adalimumab) Receives CHMP’s Positive Opinion for Inflammatory and Autoimmune Disorders Published: Dec 12, 2019 | Tags: Pfizer, Amsparity, biosimilar, adalimumab, Receives, CHMP, Positive Opinion, Inflammatory, Autoimmune Disorders 2. Janssen’s Darzalex (daratumumab) Combination Regimen Receives CHMP’s Positive Opinion for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma Published: Dec 13, 2019 | […]Read More
Copyright ©2020 PharmaShots | Powered by Octavus Consulting
